Sangart is a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion and oxygenation of ischemic (oxygen deprived) tissues through targeted oxygen delivery. 
Products
More
During more than 30 years of extensive research, Sangart has refined the pegylation of human hemoglobin to create a proprietary molecule, MP4, with the ability to perfuse oxygen deprived tissues and carry oxygen through the circulatory system to prevent and treat ischemia (oxygen deprivation of tissues).
MP4OX
MP4OX is designed to deliver oxygen in the capillaries, where red blood cells may not naturally reach when the body is suffering from trauma-related ischemia. Please click here for a short animation describing MP4OX's unique mechanism of action.
MP4CO
MP4CO is designed to deliver therapeutic levels of carbon monoxide (CO) and then provide oxygen delivery for patients with sickle cell anemia suffering from a sickle cell crisis.
Product Pipeline
Sangart is developing a number of additional, earlier stage pipeline products based on its core technology and unique understanding of oxygen delivery.
Research
More
Built on a strong foundation of scientific research, Sangart is dedicated to continuing its comprehensive clinical trial program to study and develop its products for patients in need.
Trauma
Studying MP4OX's ability to benefit patients suffering from trauma.
Sickle Cell Anemia
Studying MP4CO's ability to benefit sickle cell anemia patients.
Please click here for a broadcast segment on sickle cell disease featuring Sangart.Other Conditions
Clinical Trials
Latest News
15 Feb 2012
Sangart Enhances Leadership Team Bringing Superior Depth of Expertise12 Jan 2012
Sangart Initiates Phase 1b Study of MP4CO in Patients with Sickle Cell Disease14 June 2011
Sangart Initiates Phase 2b Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients with Hemorrhagic Shock